A multicenter team of researchers report that a commercial test designed to rule out the presence of genetic biomarkers of prostate cancer may be accurate enough to exclude the need for repeat prostate biopsies in many— if not most— men.

READ FULL ARTICLE Curated publisher From Biosciencetechnology